Answers are grounded in this paper and cite their sources.
Variability in drug response is common, with up to 70% of patients experiencing insufficient efficacy or adverse drug reactions. While genetic polymorphisms in cytochrome P450 (CYP) enzymes explain part of this variability, factors such as sex and age may also be important. This systematic review summarizes evidence on sex- and age-related differences five CYP isoforms (CYP1A2, CYP3A4, CYP2C9, CYP2C19, and CYP2D6). A search in MEDLINE, PsycINFO, and Embase identified 23 studies combining CYP genotyping and phenotyping, of which 15 contributed to the sex analysis and 6 to the age analysis. Databases were searched up to 9 February 2026. Findings were heterogeneous, reflecting differences in study design, probe substrates, and genotyping panels. Some studies suggested higher CYP1A2 activity in males, while smoking was more consistently associated with higher activity. Oral contraceptive use was consistently associated with reduced enzyme activity in females. Limited midazolam-based evidence suggested modestly higher CYP3A activity in females, while one study reported discordant findings with endogenous markers. One study suggested a decrease in CYP3A activity with age. Limited evidence from two studies suggested lower CYP2C9 activity in females. For CYP2C19, results were mixed, but oral contraceptive use reduced activity and age-related decline was reported. Limited adult evidence suggested lower CYP2D6 activity in females within genotype groups. In infants, CYP2D6 activity was detectable early and remained relatively stable throughout the first year of life. Overall, sex- and age-related differences in CYP activity appear enzyme- and context-specific, but the heterogeneous evidence does not support sex- or age-based dose adjustment.
No takes yet. Share an insight, caveat, or question.
Schaars et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: